Status epilepticus and cluster seizures in dogs: IV levetiracetam added to standard care vs standard care with placebo — MAYBE (weak evidence)

In dogs with status epilepticus or acute repetitive (cluster) seizures persisting after IV diazepam, does adding intravenous levetiracetam to standard care stop further seizures compared with standard care plus placebo?

Shelf #295 · gate-verified and displayed under the developer's blinded-trial rule

MAYBE (weak evidence): On its responder endpoint, the one emergency trial did not demonstrate a significant benefit: in Hardy 2012, 56% of dogs given IV levetiracetam had no further seizures versus 10% on placebo, but with only 19 dogs that large absolute gap missed statistical significance (P = .06); the same trial did show significantly fewer rescue diazepam boluses in the levetiracetam group (P < .03). The only other blinded, placebo-controlled trial of levetiracetam added to standard therapy in dogs (Muñana 2012, chronic oral add-on treatment in refractory epilepsy) found no significant seizure-frequency advantage over placebo (P = .310). So levetiracetam add-on is unproven rather than disproven: the emergency signal is promising but rests on a single 19-dog pilot with both levetiracetam doses pooled, no larger confirmatory trial was found, and efficacy was not demonstrated in the chronic add-on setting. Drafted Nov 10, 2026 (VetMed build, topic #295); all figures from abstracts fetched and verified at drafting.

Hardy 2012: IV levetiracetam responders 56% vs 10% on placebo — a large gap that missed significance in 19 dogs (P = .06)

Randomized, placebo-controlled, double-masked study (record's own design wording; publication type: Randomized Controlled Trial)

Who: Dogs: 19 client-owned dogs admitted for status epilepticus or acute repetitive seizures, randomised after IV diazepam to IV levetiracetam (30 or 60 mg/kg using an adaptive dose-escalation approach; n = 9 across both dose levels) or placebo (n = 10), each in addition to standard-of-care treatment, and monitored for at least 24 hours after admission for additional seizures. Seizure etiologies identified were idiopathic epilepsy (n = 10), inflammatory central nervous system disease (n = 4), intracranial neoplasia (n = 2), hepatic encephalopathy (n = 1), and 2 dogs had no cause determined.

Result: The responder rate (defined as dogs with no additional seizures after administration of the study medication) after levetiracetam was 56% compared with 10% for placebo (P = .06) — a 46-percentage-point absolute difference that did not reach statistical significance in 19 dogs. Dogs in the placebo group required significantly more boluses of diazepam compared with the levetiracetam group (P < .03). No serious adverse effects were attributable to levetiracetam administration.

Watch out: Anchor correction: the draft classed this trial as 'prospective only', but the record describes a randomized, placebo-controlled, double-masked study (publication type: Randomized Controlled Trial), and it appeared in the Journal of Veterinary Internal Medicine, not the Journal of Veterinary Emergency and Critical Care. It is nonetheless a 19-dog pilot: the two levetiracetam doses (30 and 60 mg/kg) are pooled in the responder figure, seizure causes were mixed, and the primary responder endpoint missed significance — it cannot carry a stronger stamp alone.

Hardy BT, Patterson EE, Cloyd JM, Hardy RM, Leppik IE. Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs. Journal of Veterinary Internal Medicine. 2012;26(2):334-40. PMID: 22295898. Registry ID: none in the record. MeSH: Animals · Anticonvulsants/administration & dosage · Anticonvulsants/adverse effects · Anticonvulsants/blood · Diazepam/administration & dosage · Dog Diseases/blood · Dog Diseases/drug therapy · Dogs · Double-Blind Method · Female · Half-Life · Injections, Intravenous/veterinary · Levetiracetam · Male · Pilot Projects · Piracetam/administration & dosage · Piracetam/adverse effects · Piracetam/analogs & derivatives · Piracetam/blood · Seizures/blood · Seizures/drug therapy · Seizures/veterinary · Statistics, Nonparametric · Status Epilepticus/blood · Status Epilepticus/drug therapy · Status Epilepticus/veterinary

Muñana 2012: oral levetiracetam add-on did not beat placebo on seizure frequency in refractory canine epilepsy (P = .310)

Randomized, blinded, placebo-controlled crossover trial (record's own design wording; publication types: Multicenter Study, Randomized Controlled Trial)

Who: Dogs: 34 client-owned dogs with idiopathic epilepsy resistant to phenobarbital and bromide, at three university teaching hospitals; in a crossover design each dog received levetiracetam (20 mg/kg PO q8h) or placebo for 16 weeks, then after a 4-week washout crossed over to the alternate treatment for 16 weeks. Twenty-two dogs (65%) completed the study.

Result: Weekly seizure frequency during the 1st treatment period decreased significantly during levetiracetam administration relative to baseline (1.9 ± 1.9 to 1.1 ± 1.3, P = .015). The reduction in seizures with levetiracetam was not significant when compared to placebo (1.1 ± 1.3 versus 1.5 ± 1.7, P = .310). The most common adverse event was ataxia, with no difference in incidence between levetiracetam and placebo (45 versus 18%, P = .090). Owners reported an improved quality of life with levetiracetam compared to placebo (QOL score 32.7 ± 4.3 versus 29.4 ± 4.5, P = .028).

Watch out: A different setting from the anchor: chronic oral add-on therapy for refractory epilepsy, not emergency IV treatment of status epilepticus. It is carded because it is the only other blinded, placebo-controlled trial of levetiracetam added to standard therapy in dogs, and its placebo-controlled contrast was null. Twelve of 34 dogs did not complete the study, and the authors note the study's power was limited.

Muñana KR, Thomas WB, Inzana KD, Nettifee-Osborne JA, McLucas KJ, Olby NJ, Mariani CJ, Early PJ. Evaluation of levetiracetam as adjunctive treatment for refractory canine epilepsy: a randomized, placebo-controlled, crossover trial. Journal of Veterinary Internal Medicine. 2012;26(2):341-8. PMID: 22295869. Registry ID: none in the record. MeSH: Animals · Anticonvulsants/administration & dosage · Anticonvulsants/adverse effects · Anticonvulsants/blood · Cross-Over Studies · Dog Diseases/blood · Dog Diseases/drug therapy · Dogs · Double-Blind Method · Epilepsy/blood · Epilepsy/drug therapy · Epilepsy/veterinary · Female · Levetiracetam · Male · Piracetam/administration & dosage · Piracetam/adverse effects · Piracetam/analogs & derivatives · Piracetam/blood · Quality of Life · Seizures/blood · Seizures/drug therapy · Seizures/veterinary · Statistics, Nonparametric

Synthesis: levetiracetam add-on has never beaten placebo on a primary seizure endpoint in dogs — the emergency signal is one small, borderline pilot

Synthesis

Who: Synthesis of the cards above: Hardy 2012 (19 dogs with status epilepticus or acute repetitive seizures, randomized double-masked IV levetiracetam vs placebo on top of standard care) and Muñana 2012 (34 dogs with refractory idiopathic epilepsy, randomized blinded placebo-controlled crossover of oral levetiracetam add-on; 22 completed).

Result: (1) Emergency setting: responder rates of 56% on IV levetiracetam versus 10% on placebo look large in absolute terms but were not significant (P = .06) in one 19-dog pilot; rescue diazepam use was significantly lower with levetiracetam (P < .03). (2) Chronic add-on setting: seizure frequency fell from baseline on levetiracetam but not significantly more than on placebo (P = .310). (3) Safety was consistent across both trials: no serious adverse effects attributable to levetiracetam in Hardy, and no significant excess of adverse events versus placebo in Muñana. The honest summary is that benefit is plausible and unproven, not established and not excluded.

Watch out: The two trials answer different questions (single IV dose in an emergency vs months of oral therapy in refractory epilepsy); neither should be silently transported to the other's setting. No trial of IV levetiracetam versus another active second-line drug (e.g. phenobarbital) in canine status epilepticus was found, and no larger confirmatory placebo-controlled emergency trial exists in the carded records.

Synthesis of Hardy BT et al. PMID: 22295898; Muñana KR et al. PMID: 22295869. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.